The company said net sales for Q1 2024 (3 months) were $1.889 billion, up 3.2% from the prior-year period, and rose 4.4% on a constant currency basis, which excludes the effect of currency exchange rates.

1. 01

   The company said net sales for Q1 2024 (3 months) were $1.889 billion, up 3.2% from the prior-year period, and rose 4.4% on a constant currency basis, which excludes the effect of currency exchange rates.

2. 02

   Zimmer Biomet said net earnings for Q1 2024 were $172.4 million (diluted earnings per share of $0.84), or $399.7 million on an adjusted basis (adjusted diluted earnings per share of $1.94). Net earnings for the prior-year quarter were $232.5 million.

3. 03

   The company reported net cash provided by operating activities of $228.0 million and free cash flow of $90.9 million for Q1 2024 (3 months). The prior-year period was $307.7 million and $178.2 million, respectively.

4. 04

   The company said it reiterated its full-year 2024 financial guidance. Reported revenue change is 4.5% to 5.5%, constant currency revenue change is 5.0% to 6.0%, and adjusted diluted EPS is $8.00 to $8.15.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.